VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Phase II study of camidanlumab tesirine in R/R Hodgkin lymphoma

Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses the rationale, design, and results of a Phase II study investigating the clinical efficacy and tolerability of the antibody-drug conjugate (ADC) camidanlumab tesirine in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) who have been treated with brentuximab vedotin and PD-1 inhibitors (NCT04052997). The study reported a promising activity with a long-lasting response, and showed that camidanlumab tesirine did not have an impact on subsequent transplant efficacy. In addition, patients experienced primarily hematological toxicities as well as Guillain-Barré syndrome (GBS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter